培哚普利对慢性心力衰竭患者血浆t-PA和PAI-1水平的影响

目的评价培哚普利对慢性心力衰竭(CHF)患者血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制物-1(PAI-1)水平的影响。方法采用酶联免疫吸附法测定60例CHF患者(CHF组)及20例健康人(正常对照组)血浆t-PA、PAI-1水平。CHF组患者又随机均分为常规治疗亚组和培哚普利亚组。培哚普利亚组在常规治疗基础上加用培哚普利2~4mg,每日1次。所有CHF患者治疗2周后复测血浆t-PA、PAI-1水平。结果CHF患者血浆t-PA、PAI-1水平比正常对照组明显增高(P<0.01)。治疗后,培哚普利亚组血浆PAI-1水平比常规治疗亚组明显降低(P<0.01),血浆t-PA水平比常规治疗亚组明显升高(P<0.01)。结论培哚普利不仅可降低PAI-1水平,而且可升高t-PA水平,改善内源性纤溶功能。

Effects of peidolapril on plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with chronic heart failure

Objective:To evaluate the effects of peidolapril on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in patients with chronic heart failure (CHF).Method:The levels of plasma t-PA and PAI-1 were detected in sixty patients with CHF and twenty normal controls by enzyme-linked immunosorbent assay. Sixty patients with CHF were randomized to receive peidolapril 2-4 mg daily besides conventional therapy (n=30) or only conventional therapy (n=30) for two weeks. The levels of plasma t-PA and PAI-1 were detected after treatment.Result:Compared with the normal controls, the levels of plasma t-PA and PAI-1 in patients with CHF were significantly increased (P<0.01). Administration of peidolapril was associated with the levels of significant decrease of plasma PAI-1 (P<0.01) and increase of t-PA (P<0.01).Conclusion:Peidolapril could improve fibrinolytic function of patients with CHF by decreasing plasma PAI-1 and increasing plasma t-PA levels.